<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00166816</url>
  </required_header>
  <id_info>
    <org_study_id>900604</org_study_id>
    <secondary_id>NTUH S010</secondary_id>
    <nct_id>NCT00166816</nct_id>
  </id_info>
  <brief_title>The Pharmacokinetics of Sirolimus When Combined With Cyclosporine or Tacrolimus in Renal Transplant Patients</brief_title>
  <official_title>The Pharmacokinetics and Dosage Regimen of Sirolimus in a Cyclosporine or Tacrolimus-Based Immunosuppression in Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the pharmacokinetic of sirolimus in different
      regimens, as well as the dose-level relationship of cyclosporine and tacrolimus, and design
      the most appropriate cyclosporine/sirolimus/steroid or tacrolimus/sirolimus/steroid dose
      regimen for Taiwanese.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dose and pharmacokinetic of an immunosuppressant may differ in different ethnics, and
      different combinations.

      The purpose of this study is to determine the dose-level relationship of sirolimus through
      pharmacokinetic study. The dose-level relationship of cyclosporine and tacrolimus was also
      assessed. From clinical outcome and blood level of sirolimus and cyclosporine or tacrolimus,
      we can design the most appropriate cyclosporine/sirolimus/steroid or
      tacrolimus/sirolimus/steroid dose regimen for Taiwanese.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2002</start_date>
  <completion_date>June 2003</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sirolimus in different regimens</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-concentration relationship of sirolimus</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of rejection prevention</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosage regimen of sirolimus + cyclosporine or tacrolimus</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose-concentration relationship of cyclosporine/tacrolimus</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Transplantation</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Immunosuppression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus, cyclosporine, tacrolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  De novo kidney transplantation patients, aged 13－65 years,have aminotransferase
             concentrations within 2 times the upper limit of normal.

        Exclusion Criteria:

          -  pregnancy, tuberculosis, hepatitis B or C carrier status, human immunodeficiency
             virus－positive status, retransplantation or multiorgan transplantation, or history of
             rheumatoid arthritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Po-Huang Lee</last_name>
    <role>Study Chair</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Wu FL, Tsai MK, Chen RR, Sun SW, Huang JD, Hu RH, Chen KH, Lee PH. Effects of calcineurin inhibitors on sirolimus pharmacokinetics during staggered administration in renal transplant recipients. Pharmacotherapy. 2005 May;25(5):646-53.</citation>
    <PMID>15899725</PMID>
  </results_reference>
  <verification_date>July 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2005</last_update_posted>
  <keyword>Sirolimus</keyword>
  <keyword>Tacrolimus</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Immunosuppressive Agents</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

